Christopher Wallis, MD, PhD, FRCSC

Christopher Wallis, MD, PhD, FRCSC
Assistant Professor, Division of Urology, University of Toronto
Urologic Oncologist, Division of Urology, Mount Sinai Hospital and University Health Network

Articles by Christopher Wallis, MD, PhD, FRCSC

Christopher Wallis, MD, PhD, FRCSCCRPC | October 1, 2024
Drs. Tawagi and Wallis review the PEACE-III, STAMPEDE, UpFrontPSMA, and SPLASH studies trials at the ESMO Congress 2024.
View More
Christopher Wallis, MD, PhD, FRCSCAdvanced Renal Cell Carcinoma | September 23, 2024
Drs. Karine Tawagi and Christopher Wallis review the SUNNIFORECAST and TiNivo-2 trials at the ESMO Congress 2024.
Christopher Wallis, MD, PhD, FRCSCNon-Muscle Invasive Urothelial Carcinoma | September 23, 2024
Drs. Karine Tawagi and Christopher Wallis review the SunRISe-1 and AMBASSADOR trials at the ESMO Congress 2024.
Anthony M. Joshua, MBBS, PhD, FRACPLocalized | June 13, 2024
Drs. Joshua and Wallis contextualize the Metformin Active Surveillance Trial for management of low-risk prostate cancer.
Alicia Morgans, MD, MPHCRPC | June 12, 2024
Drs. Morgans, Wallis dissect the association between PSA level of < 0.2 ng/mL and risk of radiological progression in ...
Soumyajit Roy, MDCRPC | June 6, 2024
Drs. Soumyajit Roy and Christopher Wallis break down the latest secondary analysis of the SPARTAN trial.
Christopher Wallis, MD, PhD, FRCSCnmCRPC | June 3, 2024
Darolutamide in nmCRPC shows deep PSA responses but some radiographic progression despite low PSA levels.
Christopher Wallis, MD, PhD, FRCSCLocalized | June 3, 2024
The MAST trial evaluated metformin’s effects on reducing progression of low-risk prostate cancer during active ...
Sia Daneshmand, MDASCO GU Symposium 2024 | February 6, 2024
Drs. Daneshmand and Wallis highlight two trials in progress in NMIBC: ABLE-41 and PIVOT-006.
Christopher Wallis, MD, PhD, FRCSCASCO GU Symposium 2024 | February 5, 2024
In patients with high-risk resected UC, adjuvant pembro is associated with improvement in disease-free survival.
Christopher Wallis, MD, PhD, FRCSCASCO GU Symposium 2024 | January 30, 2024
Dr. Wallis highlights his population-based research on treatment intensification shortcomings in de novo mCSPC.
Pedro Barata, MDAdvanced Renal Cell Carcinoma | May 1, 2024
Drs. Barata and Wallis highlight the efficacy of pem/len and how this IO/TKI approach compares to other strategies for aRCC.
Pedro Barata, MDASCO GU Symposium 2024 | January 30, 2024
Drs. Barata and Wallis discuss the interaction of age and benefit of treatment intensification in advanced prostate cancer.
Brad McGregor, MDASCO GU Symposium 2024 | January 26, 2024
Drs. McGregor and Wallis continue their discussion by pivoting to the BLASST-1 trial.
Brad McGregor, MDASCO GU Symposium 2024 | January 30, 2024
Drs. McGregor and Wallis highlight CONTACT-2, the first study of an ICI-based regimen to show improvement in rPFS in PC.
Karen Hoffman, MD, MHSc, MPHASCO GU Symposium 2024 | January 30, 2024
Drs. Hoffman and Wallis discuss the HRQoL from FORMULA-509 trial, showing no difference in hormonal function and fatigue.
Christopher Wallis, MD, PhD, FRCSCASCO GU Symposium 2024 | January 25, 2024
Dr. Maha Hussain presented results of the BRCAAway trial in patients with mCRPC who have HRR mutations.
Ariana L. Smith, MDSUO 2023 | December 20, 2023
Drs. Smith and Wallis shed light on how urologists can reduce risks and improve the well-being of their female patients.
Stephen J. Freedland, MDLocalized | December 12, 2023
Drs. Freedland and Wallis continue their EMBARK discussions and recommendations for treating high-risk BCR prostate cancer.
Stephen J. Freedland, MDLocalized | December 12, 2023
Drs. Freedland and Wallis discuss the details of the NEJM phase 3 EMBARK study on enzalutamide in BCR prostate cancer.